Midday Movers: Biotech Breakouts, Special Payouts, and Strategic Power Plays

September 2, 2025

DENVER, Colo., Sep 02, 2025 (247marketnews.com)- As we head towards power hour, biotechs and emerging tech names are fueling day’s action.

Ionis Pharmaceuticals (NASDAQ:IONS) is surging after announcing blockbuster results from its Phase 3 CORE and CORE2 studies evaluating olezarsen in patients with severe hypertriglyceridemia (sHTG). The therapy showed:

  • Up to 72% placebo-adjusted reduction in fasting triglycerides (p<0.0001)
  • A first-ever 85% reduction in acute pancreatitis events (p=0.0002)
  • Strong safety and tolerability across nearly 1,100 patients

“These data are groundbreaking,” said Dr. Sam Tsimikas, VP of global cardiovascular development. Ionis plans to submit a supplemental New Drug Application (sNDA) by year-end, aiming to redefine the sHTG treatment landscape.

LIXTE Biotechnology (NASDAQ:LIXT) is gaining traction following exposure in Trends in Cancer, which spotlighted a global oncology conference on “hyperactivation therapy”, a strategy that pushes cancer cells into lethal overdrive.

LB-100, LIXTE’s lead candidate, is a first-in-class PP2A inhibitor being studied for both tumor debilitation and immune activation. The dual-action approach positions LIXTE at the intersection of oncogenic stress and immunotherapy.

At the ESC Congress 2025, Cytokinetics (NASDAQ:CYTK) unveiled new data from the MAPLE-HCM trial comparing aficamten to metoprolol in hypertrophic cardiomyopathy (HCM). Results showed aficamten led to:

  • Significant improvements in cardiac structure and function
  • Atrial fibrillation incidence of just 1.5%, consistent with predicted models
  • No new safety concerns, reinforcing the positive profile ahead of the drug’s PDUFA date of December 26, 2025

Dr. Fady Malik, EVP of R&D, noted the results “elaborate on the superiority of aficamten” and strengthen its real-world viability.

Smartkem (NASDAQ:SMTK) engaged Anthony Amato of Bridge Associates International Pharmaceutical Consulting (BAIPC) to help advance its strategic initiatives. Amato, a seasoned executive who previously led BioSig Technologies (NASDAQ:BSGM) and serves on its board, will provide strategic guidance on potential partnerships and corporate development.

Chairman and CEO Ian Jenks called Amato’s addition “a valuable step” in Smartkem’s expansion plans. Amato stated that Smartkem’s platform has “the potential to change the world of electronics.”

Last week, Sound Group (NASDAQ:SOGP) announced a special dividend of $0.005 per ordinary share or $1.00 per ADS, payable to shareholders of record as of September 15, 2025.

The total distribution will amount to approximately $4 million, with payouts expected around September 30 via Deutsche Bank, the depositary of its ADS program.

Biotech & Tech Movers on the Radar

  • Relmada Therapeutics (NASDAQ:RLMD) continues to attract speculative interest as traders await updates on its depression therapy REL-1017.
  • Mineralys Therapeutics (NASDAQ:MLYS) and Glucotrack (NASDAQ:GCTK) remain on watchlists amid momentum from recent presentations and data catalysts.
  • Robot Consulting (NASDAQ:LAWR) and HWH International (NASDAQ:HWH) are showing above-average midday volume, with chatter suggesting potential near-term catalysts.

Please go to https://247marketnews.com/lixte-biotechnology/ for further LIXT information and 247marketnews.com LIXT disclosure information.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (LIXT, IONS, CYTK, SMTK, SOGP, MLYS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.